XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
Segment
$ / shares
shares
Dec. 31, 2020
$ / shares
shares
Dec. 31, 2019
shares
Dec. 12, 2021
$ / shares
Schedule Of Significant Accounting Policies [Line Items]        
Number of business segments | Segment 1      
Common stock, par value (in USD per share) | $ / shares $ 0.0001 $ 0.0001   $ 0.0001
Cash and short-term investments | $ $ 700.0      
Number of reportable business segment | Segment 1      
Total antidilutive securities excluded from calculation of diluted net loss per share (in shares) | shares 4.2 5.2 4.0  
Pfizer        
Schedule Of Significant Accounting Policies [Line Items]        
Business acquisition, share price (in usd per share) | $ / shares       $ 100.00
Transaction costs | $ $ 7.3      
Building        
Schedule Of Significant Accounting Policies [Line Items]        
Property and equipment, estimated useful life 20 years      
Minimum        
Schedule Of Significant Accounting Policies [Line Items]        
Property and equipment, estimated useful life 3 years      
Maximum        
Schedule Of Significant Accounting Policies [Line Items]        
Property and equipment, estimated useful life 15 years      
Sales revenue, net | Customer Concentration Risk | United Therapeutics        
Schedule Of Significant Accounting Policies [Line Items]        
Concentrations of risk percentage     99.00%